Feasibility Study Company Independent Feasibility Analysis

Behavioral Health & SUD Treatment · Asset Class

Behavioral Health & SUD Treatment Feasibility & Market Studies

Independent, lender-grade analysis for behavioral health and substance-use-disorder treatment facilities across SBA, conventional and specialty-healthcare, private-credit, HUD-FHA, and USDA capital. This page is our standing read on why the out-of-network billing model collapsed, how the IMD 16-bed threshold and Section 1115 waiver status gate residential Medicaid revenue, how de-novo and acquisition underwriting fails review, and the difference between the market study, the feasibility study, and the going-concern appraisal a lender requires.

Request a methodology briefing Jump to the sector monitor
41.1M
People needing SUD treatment who went untreated in 20232
26.9%
2024 drop in overdose deaths, the largest on record3
$57.7B
Cumulative opioid-settlement funding, Dec 202522
16
Bed threshold that gates adult residential Medicaid (IMD)4
The Behavioral Health Thesis

A dead revenue model, and a real one underneath it.

Behavioral health is underwritten as an operating business, not as passive real estate. The economics are hotel-like, licensed beds times census times revenue per patient day times authorized days, but reimbursement-controlled: the payer's utilization review, not the clinician, sets the days. The facility is valued as a going concern, real estate plus FF&E plus goodwill plus licenses and accreditation, so the market study and the feasibility study, not the appraisal alone, drive the credit decision. We prepare all three, aligned to the standard that will judge the file.

The defining economic fact is that the sector was built on an out-of-network commercial insurance billing model that has structurally collapsed. Facilities once billed commercial payers at high rates without a network contract and collected several times an in-network rate; that model produced the 2014–2019 boom and the private-equity gold rush, and it has been gutted by payer utilization review and denials, the No Surprises Act, in-network conversion pressure, and enforcement.25 A lender underwriting to historical out-of-network collection rates is underwriting to a revenue model that no longer exists, the single most common source of catastrophic underwriting error in this asset class.

The demand story must be held evenhandedly. The treatment gap is real and enormous, with 48.5 million people aged 12 and older reporting a past-year SUD in 2023 and 41.1 million of those needing treatment going without it.2 At the same time the sector overbuilt residential capacity on an oversold thesis, and overdose deaths fell about 26.9 percent in 2024, the largest decline on record, cutting against a perpetual-crisis narrative even as the structural gap remains.3 What follows is organized as a working desk: a national and regional supply, demand, and reimbursement monitor; the feasibility and ramp-up forensics that sink treatment-facility studies; the capital-source routing that decides which deliverable a project needs; and the study-type and program authority competitors state loosely. Every figure is dated and attributed in the sources below.

The Supply, Demand & Reimbursement Monitor

Where the behavioral health market stands, market by market.

Behavioral-health feasibility is driven less by raw demand than by structural and regulatory variables, above all state Medicaid IMD and Section 1115 waiver status. This is a structural-pressure read for the major US markets, compiled from named primary sources and sorted from highest-risk to strongest opportunity. Metro-level data is genuinely thin and is flagged as such.

The national picture frames every market. SAMHSA's 2023 National Substance Use and Mental Health Services Survey, the definitive federal facility census, covered 20,681 eligible facilities, including 14,620 substance-use and 9,856 mental-health facilities, and SAMHSA had certified 2,151 opioid treatment programs as of May 2024.19 Demand is genuinely contested and must be presented evenhandedly: the treatment gap is enormous, the sector overbuilt residential on an oversold out-of-network thesis, and overdose deaths fell to an estimated 80,391 in 2024, down 26.9 percent from 110,037 in 2023, with a further decline projected into 2026.3 The largest stand-alone operator, Acadia Healthcare, ran a network of 258 facilities with roughly 11,400 beds across 38 states and Puerto Rico as of June 30, 2024.15 The result is a market where demand is real but the viable revenue future is in-network commercial, Medicaid, OTP, and outpatient or CCBHC assets, not the collapsed out-of-network residential model.

Structural pressure: Oversupplied Constrained Underserved / opportunity. Read is structural and regulatory, not a rent or vacancy figure; confirm current Section 1115 waiver status on the KFF tracker, since counts shift.
Market / segment Structural profile Enforcement & fraud flag Underwriting read Pressure
South FloridaResidential overbuilt; "Florida Shuffle" originHighest patient-acquisition costMost aggressively enforced patient-brokering statuteDe-novo residential highest-riskOversupplied
Southern CaliforniaOversupplied residential bedsEKRA epicenter; US v. Schena, 9th Cir. July 2025In-network / reposition onlyOversupplied
ArizonaAHCCCS sober-living scandal, ~$2.8B; 40+ deaths42 arrests June 2025; new probes fell to 270 by Aug 2025Reputational contagionOversupplied
UtahOversupplied; sanction precedentHighland Ridge Hospital closed 2024Elevated licensure scrutinySelective; repositionConstrained
Non-waiver states (>16-bed residential)Cannot bill Medicaid for adults 21–64Structural, not enforcementSize to ≤16 beds or route commercial / OTPConstrained
OTP / OBOT (national)High-barrier, Medicaid-heavy, stable~30% of OTPs PE-owned42 CFR Part 8 modernized 2024Barrier-to-entry license premiumUnderserved
CCBHC / outpatient mental healthEnhanced, cost-based Medicaid PPS ratePermanent Medicaid option, 2024Expanding, under-covered opportunityUnderserved
Rural treatment desertsUnderserved; telehealth & mobile-unit flexibilitiesLower saturation and scrutinyUSDA Community Facilities financingUnderserved

Compiled from SAMHSA N-SUMHSS and OTP guidelines, KFF's Section 1115 waiver tracker, the Arizona Attorney General, DOJ and National Law Review, Axios Phoenix, AZCIR, Penn LDI, and USDA Rural Development; see sources 1, 4, 7–9, 14, 18, and 21. Overdose-rate variation is extreme, from 3.3 per 100,000 in Nebraska to 38.6 in West Virginia in 2024, with all states declining year over year. Feasibility studies should build market-specific bed-supply and payer-mix counts from N-SUMHSS state profiles, state licensure rosters, and the KFF waiver tracker rather than national averages.

The reimbursement number depends entirely on which basis you mean

No figure in this sector is more misused than revenue per patient day. Billed charges, allowed amounts, and collected revenue are three distinct bases that must never be conflated, and payer bases differ by a factor of 5 to 10 times: in-network commercial, out-of-network commercial, Medicaid, Medicare, and private-pay are separate universes. Commercial reimbursement for residential addiction treatment is often quoted at roughly $800 to $1,500 or more per bed per day, with PHP near $400 to $900, but those are billed or allowed reference points, not collected revenue; Medicaid rates are materially lower and set by state.6 Behavioral-health claim denial rates rose from 10.2 percent to 11.8 percent in 2024, with Medicare Advantage denying 15.7 percent and commercial payers 13.9 percent.25 Any pro forma that cites a per-diem without stating its basis and payer is not defensible.

Length of stay is payer-controlled and has compressed

The critical revenue variable is authorized length of stay, and payers set it through utilization review. Average authorized residential LOS has compressed from a historical 28- to 30-plus-day norm toward roughly 10 to 20 authorized days, and national claims data show a median hospital rehabilitation or residential LOS of 6 days and a detox LOS of 4 days.17 Compressed LOS collapses revenue per admission and forces higher admission volume to fill the same beds, at a patient-acquisition cost that can run several thousand dollars per admission. Revenue per admission and revenue per patient day are different bases and must not be conflated; a model that assumes a 28- to 30-day stay while payers authorize 10 to 14 overstates revenue per bed by a wide margin.

Market-size figures diverge by up to 60x, and multiples have repriced

Dollar-market estimates diverge by up to roughly 60 times because vendors measure different things: the narrow addiction-treatment medication basis is valued near $2.3 to $2.4 billion in 2024, while the broad treatment-centers basis is estimated at $143.6 billion, with US behavioral-health estimates ranging roughly $47 to $97 billion depending on scope; all are directional only.26 Behavioral-health EBITDA multiples compressed roughly one-third over five years from the 2020–2022 peak; standalone SUD trades at the low end, near a 9.5x mean versus 11.4x for co-occurring, and brokers cite accredited residential at 5x to 8x with a discount for non-accredited or out-of-network-dependent programs.1213 Private-equity firms now own about 30 percent of US opioid treatment programs, one of the highest ownership levels in any sector of medicine, and current PE posture has pivoted to in-network, Medicaid, OTP, and outpatient assets.14

Common Review Failures

How behavioral health feasibility and underwriting fail review.

Payer mix, length of stay, the regulatory gates, and compliance history are the variables a credit committee scrutinizes most, and the places treatment-facility studies most often break. Each failure below is tied to a real mechanism or number.

  1. Underwriting to a dead out-of-network model

    The number-one catastrophic error: forecasting on historical out-of-network commercial collection rates that no longer exist. Payer denials, aggressive utilization review, the No Surprises Act, and network-adequacy pressure have gutted OON economics, and denial rates rose to 11.8 percent in 2024. A pro forma dependent on OON collections is built on sand.25

  2. Billed-versus-collected and payer-mix mis-modeling

    Blending payer rates, or using billed charges rather than collected revenue, is the most dangerous confusion in the sector. Overestimating the commercial mix in a Medicaid-dominated market, or treating a $1,500 billed per-diem as collected revenue, overstates income before a single day is authorized. Require trailing 12 to 24 months of collected-revenue and denial data.6

  3. Length-of-stay compression ignored

    Modeling a 28- to 30-day residential stay when payers authorize 10 to 20 days, or fewer, collapses revenue per admission and requires far higher admission volume to fill the same beds. Claims data show a median residential LOS of 6 days and detox of 4. Stress authorized LOS downward and extend the census ramp.17

  4. The IMD-exclusion / 16-bed trap

    Building a greater-than-16-bed residential facility in a non-waiver state and only then discovering it cannot bill Medicaid for adults aged 21 to 64, eliminating the largest payer by volume. Confirm Section 1115 SUD waiver status and bed count against the 16-bed threshold before sizing; this gate drives facility sizing more than demand does.4

  5. Licensure and accreditation timeline under-reserved

    A facility cannot bill commercial payers without accreditation, and generally cannot be surveyed for accreditation until it has operated. The 6-to-18-month gap between opening and full billing capability is the classic de-novo killer and is routinely under-reserved. Reserve 12 to 18 months of working capital, or restructure.13

  6. Patient-acquisition cost under-modeled

    Marketing and lead-generation cost per admission can run into five figures; certified centers in competitive markets report cost-per-lead of $150 to $280 per qualified inquiry and pay-per-call at $200 to $500. LegitScript certification is mandatory to advertise, and EKRA prohibits paying for referrals, so per-head and pay-per-admission structures are unlawful.18

  7. Compliance-diligence failure

    Failing to diligence a target's patient-brokering, urine-drug-testing and lab, marketing, and billing practices; an acquirer inherits the liability. EKRA carries penalties up to $200,000 and 10 years per occurrence, and in-house-lab or paid-referral arrangements are specific red flags. Unresolved compliance red flags are a decline.7

  8. Grant and settlement money booked as recurring

    Opioid-settlement funds, which reached $57.7 billion cumulatively by December 2025, and SAMHSA grants are real tailwinds, but they are not recurring reimbursement and carry renewal and appropriation risk. Segregate them and stress to zero at renewal; grant or settlement revenue above 15 to 20 percent of the pro forma without segregation should trigger a reprice.22

Capital-Source Routing

Which channel funds the project, and what it requires.

Behavioral health routes through operating-business and specialty-healthcare channels, and each requires a different deliverable and standard. The study is built to the union of requirements across the channels actually in play, and the first questions are always the payer mix, the level of care, and the IMD and waiver posture.

The behavioral health lender matrix
Deliverable and program terms by capital source. Terms are program conventions, not universal minimums.19
Capital sourceDeliverableProgram terms
SBA 7(a) / 504Going-concern feasibility for the operating businessEligible under SOP 50 10 8 (June 1, 2025); SBSS min raised 155→165
Conventional / specialty healthcare & ABLFeasibility plus payer-AR analysisAsset-based lending against payer receivables
Private equity / private creditPlatform-level going-concern modelEBITDA-multiple entry; the dominant platform capital
HUD-FHA Section 242FHA hospital mortgage insurance (psychiatric / specialty)24 CFR Part 242; up to 25-year term, up to 90% LTV
HUD-FHA Section 232Residential-care mortgage insuranceOriented to senior / long-term care; limited BH applicability
USDA Community FacilitiesNonprofit / public rural facilities (pop. ≤20,000)Direct loan / grant; $5M opioid-epidemic set-aside

Sources: SBA SOP 50 10 8; HUD Sections 242 and 232; USDA Rural Development Community Facilities program. See sources 19, 20, and 21.

One revenue-quality trap is worth stating plainly, because sponsors hit it constantly: grant and settlement money is not reimbursement. SAMHSA State Opioid Response and block grants, CCBHC expansion grants, and opioid-settlement funds, which reached $57.7 billion cumulatively as of December 16, 2025 and are paid by 13 or more companies over roughly 18 years, are material funding streams, but they carry renewal and appropriation risk and must not be underwritten as recurring cash flow.22 The going- concern value should never rely on out-of-network or grant revenue. Facility real estate is analyzed separately with a going-dark test: a converted residential or hospitality asset retains genuine alternative use and supports collateral, while a purpose-built psychiatric hospital is far more specialized with weaker going-dark value.

  • Residential / inpatient (>16 beds)Confirm state Section 1115 waiver status first; SBA 504 or specialty-healthcare lending, sized against the IMD threshold.
  • Opioid treatment program (methadone) or OBOT (buprenorphine)SBA or private equity / private credit; requires SAMHSA certification, DEA registration, state approval, and 42 CFR Part 8.
  • PHP / IOP outpatientConventional or SBA; commercial plus Medicare IOP coverage, effective 2024, with better payer acceptance than residential.
  • CCBHC or outpatient mental healthNonprofit or public: USDA Community Facilities, NMTC / CDFI mission lending; enhanced cost-based Medicaid PPS.
  • Rural or underserved marketUSDA Community Facilities (pop. ≤20,000), with the $5M opioid set-aside; CCBHC, OTP, and telehealth opportunity.
  • Recovery residence / sober livingGenerally unlicensed and not reimbursed (charges rent); FHA/ADA-protected dwelling, NARR-certified; the heaviest fraud history.
Study Types

Market study, feasibility study, appraisal: three questions.

These three documents answer different questions and are not substitutes. Sponsors and lenders conflate them constantly; specialty-healthcare underwriters and accreditation surveyors do not.

What each document answers, and the standard or basis that governs it.
DocumentQuestion answeredGoverning standard / basis
AppraisalWhat is it worth? Going-concern value, real estate plus FF&E plus goodwill plus licenses, with a going-dark analysis.USPAP
Market studyWill it fill? Demand, supply, payer mix, bed saturation, and competition, without the site-specific model.N-SUMHSS, KFF waiver tracker, state licensure rosters
Feasibility studyWill it fill, license, staff, and repay? The census, LOS, payer-mix, and ramp model plus the regulatory gates.Lender underwriting plus ASAM and accreditation gates

The licensure framework is the ASAM Criteria, levels 0.5 through 4.0, increasingly written into state licensure and payer contracts; a facility must be licensed at the level it bills, and the licensure timeline, often 6 to 12 months or more, is a de-novo gate. Most commercial payers and many Medicaid programs additionally require Joint Commission or CARF accreditation, which generally requires a period of operation before survey and supports roughly a half-turn to full-turn EBITDA premium at sale.13 Opioid treatment programs are governed by a distinct regime: SAMHSA certification, DEA registration, state approval, and 42 CFR Part 8, modernized in the February 2, 2024 final rule, effective April 2, 2024, the most substantive change in over 20 years, which expanded take-home methadone and telehealth initiation.10 The Consolidated Appropriations Act, 2023 eliminated the DATA-2000 X-waiver, so any DEA-registered practitioner with Schedule III authority can now prescribe buprenorphine.11

Two further structures are distinctive to this asset class. The 42 CFR Part 2 confidentiality protection for SUD records was aligned more closely with HIPAA in the 2024 final rule, with a single-consent provision and further changes effective February 16, 2026.28 And persons in recovery are protected as persons with disabilities under the Fair Housing Act and the ADA, so municipalities generally cannot zone out recovery residences and must grant reasonable accommodations, though the FHA protects dwellings, meaning a primarily clinical treatment facility may not be a protected dwelling, so the residence-versus-clinical-facility distinction materially changes the siting analysis.27 Psychiatric hospitals are a separate category with their own Medicare Inpatient Psychiatric Facility PPS; the FY2026 federal per diem base rate is $892.87 for quality-reporting-compliant facilities.24

Behavioral health sub-segments, each with a distinct study scope

Behavioral Health Questions

Behavioral health feasibility and market-study questions.

What is the difference between a behavioral health market study and a feasibility study?

A market study sizes demand, supply, payer mix, bed saturation, and competition for a behavioral health or SUD treatment facility. A feasibility study tests whether a specific project can be financed, licensed, staffed, filled, and repaid, integrating the census, length-of-stay, payer-mix, and ramp model with the regulatory gates, from the IMD 16-bed threshold and Section 1115 waiver status to ASAM licensure and Joint Commission or CARF accreditation. An appraisal opines on value. The facility is valued as a going concern, not passive real estate, so the feasibility study drives the credit decision.

What is the Medicaid IMD exclusion and the 16-bed threshold?

Since Medicaid's 1965 enactment, federal law bars federal Medicaid payment for adults aged 21 to 64 who are patients in an institution for mental diseases, defined as a facility of more than 16 beds primarily treating mental disease, under Section 1905(i) of the Social Security Act. Many residential facilities are built at exactly 16 beds to stay under it. Section 1115 SUD waivers, introduced in 2015 and updated in 2017, let states draw federal Medicaid funds for short-term IMD residential SUD stays subject to conditions including a 30-day statewide-average length of stay and ASAM-aligned care. A residential facility above 16 beds in a non-waiver state simply cannot bill Medicaid for adult residential treatment, eliminating the largest payer by volume, so this gate drives facility sizing and market selection more than demand does. Confirm current state status on the KFF waiver tracker.

Why is out-of-network commercial revenue an underwriting red flag?

The residential addiction sector was built on an out-of-network commercial billing model, in which facilities billed commercial payers at high rates without a network contract and collected several times what an in-network facility would receive. That model has structurally collapsed under payer utilization review and denials, the No Surprises Act effective January 1, 2022, network-adequacy and in-network conversion pressure, and enforcement. Behavioral health claim denial rates rose from 10.2 percent to 11.8 percent in 2024. A pro forma built on historical out-of-network collections is underwriting to a revenue model that no longer exists, which is the single most common source of catastrophic underwriting error in the sector.

Can a behavioral health or SUD treatment facility be financed with an SBA loan?

Yes. Behavioral health and SUD treatment facilities are SBA-eligible as for-profit healthcare operating businesses under SOP 50 10 8, effective June 1, 2025. The 504 program finances the real estate, and the 7(a) program finances business acquisition, change of ownership, and working capital. SBA scrutiny is heightened given the sector's fraud history and regulatory risk, and the de-novo working-capital gap between opening and full licensure and accreditation is a challenge that must be reserved for. SOP 50 10 8 also raised the minimum SBSS score for 7(a) from 155 to 165 and restored pre-2021 underwriting.

What licensure, accreditation, and certification does a treatment facility need?

State licensure is by ASAM level of care, and a facility must be licensed at the level it bills, with a licensure timeline often running 6 to 12 months or more. Most commercial payers and many Medicaid programs require Joint Commission or CARF accreditation, which generally requires a period of operation before survey, creating a de-novo cash-flow trap. Opioid treatment programs additionally require SAMHSA certification, DEA registration, state approval, and 42 CFR Part 8 compliance, which was modernized in the February 2024 final rule effective April 2, 2024. Accreditation supports roughly a half-turn to full-turn EBITDA premium at sale.

What is EKRA and why does it matter for marketing?

The Eliminating Kickbacks in Recovery Act, 18 U.S.C. Section 220, enacted in 2018, criminalizes paying or soliciting remuneration for referrals to recovery homes, clinical treatment facilities, or laboratories across all payers, including commercial, with penalties up to $200,000 and 10 years per occurrence. It is broader than the Anti-Kickback Statute, which reaches only federal programs. EKRA makes per-head marketing and pay-per-admission affiliate structures unlawful, so call-center and lead-generation contracts must be restructured to flat-fee or W-2 employee models. Since May 2018, Google, Meta, and Microsoft also require LegitScript certification to advertise addiction-treatment services. Patient-acquisition cost, often running into five figures per admission, is a defining and under-modeled expense.

Are opioid-settlement and SAMHSA grant funds underwritable as recurring revenue?

No. Opioid-settlement funds, which reached $57.7 billion cumulatively as of December 16, 2025, along with SAMHSA State Opioid Response and block grants and CCBHC expansion grants, are material public-funding tailwinds, but they are not the same as recurring reimbursement and carry renewal and appropriation risk. They must be segregated from the pro forma and stressed to zero at renewal. A common benchmark is that grant or settlement revenue exceeding 15 to 20 percent of the pro forma without segregation should trigger a reprice.

By Market

Behavioral health feasibility studies by state.

Behavioral-health feasibility is local and regulatory. Explore the state markets where the Section 1115 waiver status, the licensure and ASAM regime, the enforcement climate, and bed saturation determine whether a project pencils.

Underwriting a treatment facility? Start with the payer and regulatory read.

Feasibility Study Company prepares independent Behavioral Health & SUD Treatment feasibility and market studies, built to the review standard your capital source applies. A methodology briefing walks through the analytical framework, the deliverable your capital source requires, the IMD and Section 1115 posture for your market, and the collected-revenue, LOS, and compliance data that decide whether a project pencils.

Request a methodology briefing
Sources

Data sources and dates.

Every figure on this page traces to a named authority. Metrics are labeled by basis and payer and must not be compared across incompatible bases; billed charges, allowed amounts, and collected revenue are distinct. Vendor market-size figures are directional only.

  1. SAMHSA, 2023 National Substance Use and Mental Health Services Survey (N-SUMHSS), Publication No. PEP24-07-027 (December 2024): facility census, 20,681 eligible facilities.
  2. SAMHSA, National Survey on Drug Use and Health (NSDUH), 2023 and 2024, with NACo summary: SUD prevalence and the treatment gap (48.5 million with past-year SUD; 41.1 million untreated in 2023).
  3. CDC/NCHS provisional drug-overdose death data (May 14, 2025) and CDC/NVSS 12-month-ending estimates (June 17, 2026); KFF using CDC WONDER (2024) for state overdose rates.
  4. Social Security Act §1905(i); Congressional Research Service IF10222; Congressional Budget Office (April 2023): the IMD exclusion and 16-bed threshold.
  5. KFF Medicaid Section 1115 waiver tracker; Behavioral Health Business Broker (2026): Section 1115 SUD/IMD waiver status (one source cites 37-plus states; counts vary by tracker and date).
  6. Behavioral Health Business / ADSC (2024): commercial residential per-diem (~$800–$1,500+) and PHP (~$400–$900) reference ranges; figures are billed or allowed, not collected.
  7. Eliminating Kickbacks in Recovery Act, 18 U.S.C. §220 (enacted 2018); U.S. Department of Justice; National Law Review (2026); US v. Schena, 9th Cir. (July 2025).
  8. Arizona Attorney General; Axios Phoenix (June 9, 2026); Native News Online; AZCIR: the AHCCCS sober-living Medicaid fraud (~$2.8 billion; 42 arrests June 2025).
  9. SAMHSA, Federal Guidelines for Opioid Treatment Programs, HHS Pub. No. PEP24-02-011 (2024): OTP certification counts (2,151 as of May 2024).
  10. Federal Register, 89 FR 7549; SAMHSA 42 CFR Part 8 final rule (February 2, 2024; effective April 2, 2024; compliance October 2, 2024).
  11. Consolidated Appropriations Act, 2023, §1262 (X-waiver elimination); DEA; SAMHSA; NEJM (2024): buprenorphine prescriber growth.
  12. Edgemont Partners (Fall 2025) and PitchBook: behavioral-health EBITDA multiples and standalone-SUD versus co-occurring means.
  13. Scope Research; Behavioral Health Business Broker (2026); Vallexa Advisors: transaction multiples and the accreditation EBITDA premium.
  14. Penn LDI (2026); Singh et al., Health Affairs 2025;44(9):1181–1189 (September 2, 2025): private-equity ownership of OTPs (~30 percent).
  15. Acadia Healthcare, Business Wire (July 31, 2024) and 8-K (September 2024); New York Times; Becker's (2024–2025); U.S. Senate Finance Committee report (June 2024).
  16. U.S. Department of Labor fact sheet (2024); MHPAEA final rule (September 9, 2024); DOL/HHS/Treasury non-enforcement announcement (May 15, 2025).
  17. Peterson-KFF Health System Tracker (2023 MarketScan): median hospital rehabilitation/residential LOS of 6 days and detox LOS of 4 days.
  18. LeadsuiteNow (2026); Circle Social; Behavioral Health Partners (2026): patient-acquisition cost, cost-per-lead, and LegitScript certification (required by Google, Meta, Microsoft since May 2018).
  19. U.S. Small Business Administration, SOP 50 10 8 (effective June 1, 2025): 7(a) and 504 eligibility for behavioral health operating businesses; SBSS minimum raised from 155 to 165.
  20. U.S. Department of Housing and Urban Development, FHA Section 242 hospital mortgage insurance (24 CFR Part 242) and Section 232 residential-care mortgage insurance.
  21. USDA Rural Development, Community Facilities program (2013–2019), $5,000,000 opioid-epidemic set-aside; CRS R48462: rural behavioral-health and recovery-housing financing.
  22. Opioid Settlement Tracker / GrantFinder Funding Report (December 16, 2025) and KFF Health News: cumulative opioid-settlement funding of $57.7 billion; SAMHSA grants.
  23. Medicaid.gov; Consolidated Appropriations Act of 2024, §209 (signed March 9, 2024); CRS IF12494: CCBHC as a permanent Medicaid option and the enhanced PPS methodology.
  24. CMS-1831-F, Inpatient Psychiatric Facility PPS FY2026 final rule (effective October 1, 2025); CMS MLN Matters MM14206; AJMC (citing Gorman 2025): $892.87 per diem base rate; psychiatric-bed capacity.
  25. Arise Billing Solutions (2024), citing industry data: behavioral-health claim-denial rates (10.2 to 11.8 percent in 2024; Medicare Advantage 15.7 percent; commercial 13.9 percent).
  26. Grand View Research (2024); Market Data Forecast (2025); Precedence Research (2024); Fortune Business Insights; Statifacts; Towards Healthcare/Precedence (2026): market-size estimates (~$2.3 billion to ~$143.6 billion; directional only).
  27. DOJ/HUD Joint Statement on Group Homes; City of Edmonds v. Oxford House; Caldera, LLC v. City of Claremont, NH (preliminary ruling): Fair Housing Act, ADA, and zoning framework.
  28. SAMHSA/HHS 42 CFR Part 2 final rule (2024): SUD-record confidentiality aligned with HIPAA; single-consent and further changes effective February 16, 2026.